07.03.2013 - Swedish Active Biotech has issued new shares to obtain money for its clinical autoimmunity and cancer programmes.
Active Biotech’s Board announced that the Lund-based company will issue 6 million new shares to Investor AB at SEK45 per share, creating up to SEK270m (€32.4m). The company said it will use the proceeds to strengthen its capital base and to advance development and value-creation of its programmes. Currently, the company has two programmes in pivotal clinical studies: Active Biotech’s Phase III renal cancer candidate drug ANYARA is managed and financed on a proprietary basis, while its multiple sclerosis drug laquinimod is partnered with Teva. The firm’s Phase II prostate cancer candidate TASQ is co-developed with Ipsen, while the firm’s preclinical candidates ISI and 57-57 are still unpartnered. The fresh capital strengthens Active Biotech's position in discussions with potential partners.
Active Biotech's two largest shareholders MGA Holding AB and Nordstjernan AB, and East Bay AB, who have 44% of shares each, said they would support the new issue. Through the new issue, the number of shares will increase 68,923,582 to 74,923,582 and the share capital will increase by from SEK 259,796,597.53 to SEK 282,412,653.46.
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.
14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.